All
FDA Grants Priority Review to Adcetris Consolidation in Hodgkin Lymphoma
April 22nd 2015The FDA has granted a priority review to the antibody-drug conjugate Adcetris as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression.
Xalkori Granted Breakthrough Designation for ROS1-Positive Lung Cancer
April 21st 2015The Food and Drug Administration has granted a breakthrough therapy designation to Xalkori (crizotinib) as a potential treatment for patients with ROS1-positive non–small cell lung cancer, based on phase 1 findings published in the New England Journal of Medicine.
Long-Term Aspirin Use Decreases Risk of Gastrointestinal Cancers, Especially Colorectal
April 20th 2015A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.
Early Phase Study Shows MM-302 Has Activity in Heavily-Pretreated HER2-Positive Breast Cancer
April 20th 2015MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.
Telephone Intervention Helps Breast Cancer Survivors Set—and Meet—Lifestyle Goals
April 15th 2015A new telephone-based intervention for breast cancer survivors is showing promise, and it involves them becoming more actively engaged in goal setting and problem solving with an eye toward accelerating their recovery by engaging in health-promoting activities such as exercise, stress management and healthy eating.
Low Vitamin D Levels Linked to Worse Outcomes in Follicular Lymphoma
April 14th 2015A new study has found that patients with lower vitamin D levels prior to treatment for follicular lymphoma are more likely to die or relapse from the disease earlier than patients with adequate vitamin D levels in their blood.